Advanced Basal Cell Carcinoma: How to Navigate Challenging Clinical Scenarios with Systemic Treatment

To participate in this activity, please:

Sign in Sign Up

Basal cell carcinoma (BCC) is a common type of skin cancer that can be challenging to treat in advanced stages. Join Karl Lewis, MD, and Aleksandar Sekulic, MD, PhD, as they discuss the importance of the hedgehog pathway in the pathogenesis of BCC and the role of hedgehog inhibitors in advanced BCC. Evidence related to the safety and efficacy of the approved hedgehog inhibitors sonidegib and vismodegib is discussed, with recommendations for optimizing their use. Case studies are utilized to share the faculty’s experience in treating patients with hedgehog inhibitors, including strategies to manage resistance.

As in medicine generally, the management of patients with locally advanced basal cell carcinoma is rapidly evolving. To help clinicians keep abreast of new information, this CME activity will be updated 4 times through October 2021.  This first update has been posted and includes information released between February 17 and April 7, 2021.

 

Course Credit:

2.00 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2021-02-17
Closes: 2022-02-17

Target Audience:

This activity is intended for a national audience of oncologists, dermatologists, dermato-oncologists, and Mohs surgeons.

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Complete CME Details
  • Karl D. Lewis, MD

    Associate Professor of Medicine
    Division of Medical Oncology
    University of Colorado
    Medical Oncologist
    UCH - Cancer Center
    Aurora, Colorado

  • Aleksandar Sekulic, MD, PhD

    Deputy Director, Mayo Clinic Cancer Center
    Associate Director, Center for Individualized Medicine
    Vice Chair, Department of Dermatology
    Chair, Cutaneous Oncology Disease Group
    Mayo Clinic Scottsdale
    Scottsdale, Arizona

Learning Objectives

  • Explain how the target pathways of systemic treatment for advanced basal cell carcinoma (BCC) align with the current understanding of the pathogenesis of the disease
  • Evaluate the profiles of and clinical data related to current and emerging systemic treatments to support the optimal care of patients with advanced BCC
  • Create systemic treatment plans for patients with advanced BCC who are intolerant to hedgehog pathway inhibitors
  • Identify opportunities to improve the management of patients with advanced BCC whose disease has progressed despite previous treatment with hedgehog pathway inhibitors

Faculty Disclosures

Karl D. Lewis, MD

Advisory Board: Regeneron, Eisai


Aleksandar Sekulic, MD, PhD

No relationships to disclose.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.